Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?
Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under